Evolutionary Genomics Overview
Latest ROE for Evolutionary Genomics: 33.18% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow33.18%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for FNAM is 33.18%. That is above the Healthcare sector average of 11.15%. Investors often review this figure alongside Evolutionary Genomics's historical trend and sector peers before judging valuation or financial health.
Against Healthcare companies, FNAM currently prints 33.18% for ROE, while the sector average sits near 11.15%. That is roughly 197.4% above the sector mean. Large gaps often invite a closer look at Evolutionary Genomics's growth, margins, and balance sheet.
Return on Equity shows how effectively Evolutionary Genomics converts resources into returns. At 33.18%, FNAM may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting FNAM's ROE (33.18%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Evolutionary Genomics's ROE against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.
